Nick P. G. Gauthier

Nick P. G. Gauthier

Auto-generated profile, based on publicly available information

Nick P. G. Gauthier

Department of Microbiology and Immunology, University of British Columbia , Vancouver, British Columbia

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
23 March 2023 in Clinical Microbiology Reviews
Verified
Journal Article
Closed access
NGNick P. G. Gauthier
Nick P. G. Gauthier
SCSamuel D. Chorlton
Samuel D. Chorlton
MKMel Krajden
Mel Krajden
AMAmee R. Manges
Amee R. Manges
The advent of next-generation sequencing (NGS) technologies has expanded our ability to detect and analyze microbial genomes and has yielded novel molecular approaches for infectious disease diagnostics. While several targeted multiplex PCR and NGS-based assays have been widely used in public health settings in recent years, these targeted approaches are limited in that they still rely on a priori knowledge of a pathogen’s genome, and an untargeted or unknown pathogen will not be detected.

2 May 2024 in The Journal of Infectious Diseases
Verified
Journal Article
Open access
PDF file
NGNick P G Gauthier
Nick P G Gauthier
WCWilson Chan
Wilson Chan
KLKerstin Locher
Kerstin Locher
DSDuane Smailus
Duane Smailus
RCRobin Coope
Robin Coope
AMAmee R Manges
Amee R Manges
Current molecular diagnostics are limited in the number and type of detectable pathogens. Metagenomic next generation sequencing (mNGS) is an emerging, and increasingly feasible, pathogen-agnostic diagnostic approach. Translational barriers prohibit the widespread adoption of this technology in clinical laboratories. We validate an end-to-end mNGS assay for detection of respiratory viruses. Our assay is optimized to reduce turnaround time, lower cost-per-sample, increase throughput, and deploy secure and actionable bioinformatic results. We validated our assay using residual nasopharyngeal swab specimens from Vancouver General Hospital (n = 359), RT-PCR-positive, or negative for Influenza, SARS-CoV-2, and RSV. We quantified sample stability, assay precision, the effect of background nucleic acid levels, and analytical limits of detection. Diagnostic performance metrics were estimated. We report that our mNGS assay is highly precise, semi-quantitative, with analytical limits of detection ranging from 103-104 copies/mL. Our assay is highly specific (100%) and sensitive (61.9% Overall: 86.8%; RT-PCR Ct < 30). Multiplexing capabilities enable processing of up to 55-specimens simultaneously on an Oxford Nanopore GridION device, with results reported within 12-hours. This study outlines the diagnostic performance and feasibility of mNGS for respiratory viral diagnostics, infection control, and public health surveillance. We addressed translational barriers to widespread mNGS adoption.

14 October 2022 in PLOS ONE
Verified
Journal Article
Open access
PDF file
NGNick P. G. Gauthier
Nick P. G. Gauthier
KLKerstin Locher
Kerstin Locher
CMClayton MacDonald
Clayton MacDonald
SCSamuel D. Chorlton
Samuel D. Chorlton
MCMarthe Charles
Marthe Charles
AMAmee R. Manges
Amee R. Manges
Objectives: The COVID-19 pandemic and ensuing public health emergency has emphasized the need to study SARS-CoV-2 pathogenesis. The human microbiome has been shown to regulate the host immune system and may influence host susceptibility to viral infection, as well as disease severity. Several studies have assessed whether compositional alterations in the nasopharyngeal microbiota are associated with SARS-CoV-2 infection. However, the results of these studies were varied, and many did not account for disease severity. This study aims to examine whether compositional differences in the nasopharyngeal microbiota are associated with SARS-CoV-2 infection status and disease severity. Methods: We performed Nanopore full-length 16S rRNA sequencing on 194 nasopharyngeal swab specimens from hospitalized and community-dwelling SARS-CoV-2-infected and uninfected individuals. Sequence data analysis was performed using the BugSeq 16S analysis pipeline. Results: We found significant beta (PERMANOVA p < 0.05), but not alpha (Kruskal-Wallis p > 0.05) diversity differences in the nasopharyngeal microbiota among our study groups. We identified several differentially abundant taxa associated with SARS-CoV-2 infection status and disease severity using ALDEx2. Finally, we observed a trend towards higher abundance of Enterobacteriaceae in specimens from hospitalized SARS-CoV-2-infected patients. Conclusions: This study identified several alterations in the nasopharyngeal microbiome associated with SARS-CoV-2 infection status and disease severity. Understanding the role of the microbiome in infection susceptibility and severity may open new avenues of research for disease prevention and treatment.

13 June 2022 in medRxiv
Verified
Preprint
Open access
PDF file
NGNick P.G. Gauthier
Nick P.G. Gauthier
KLKerstin Locher
Kerstin Locher
CMClayton MacDonald
Clayton MacDonald
SCSamuel Chorlton
Samuel Chorlton
MCMarthe Charles
Marthe Charles
AMAmee R. Manges
Amee R. Manges
Objectives: The COVID-19 pandemic and ensuing public health emergency has emphasized the need to study SARS-CoV-2 pathogenesis. The human microbiome has been shown to regulate the host immune system and may influence host susceptibility to viral infection, as well as disease severity. Several studies have assessed whether compositional alterations in the nasopharyngeal microbiota are associated with SARS-CoV-2 infection. However, the results of these studies were varied, and many did not account for disease severity. This study aims to examine whether compositional differences in the nasopharyngeal microbiota are associated with SARS-CoV-2 infection status and disease severity. Methods: We performed Nanopore full-length 16S rRNA sequencing on 194 nasopharyngeal swab specimens from hospitalized and community-dwelling SARS-CoV-2-infected and uninfected individuals. Sequence data analysis was performed using the BugSeq 16S analysis pipeline. Results: We found significant beta (PERMANOVA p < 0.05), but not alpha (Kruskal-Wallis p > 0.05) diversity differences in the nasopharyngeal microbiota among our study groups. We identified several differentially abundant taxa associated with SARS-CoV-2 infection status and disease severity using ALDEx2. Finally, we observed a trend towards higher abundance of Enterobacteriaceae in specimens from hospitalized SARS-CoV-2-infected patients. Conclusions: This study identified several alterations in the nasopharyngeal microbiome associated with SARS-CoV-2 infection status and disease severity. Understanding the role of the microbiome in infection susceptibility and severity may open new avenues of research for disease prevention and treatment.

16 June 2025 in Clinical Microbiology Newsletter
Verified
Journal Article
Open access
GAGeneviève Amaral
Geneviève Amaral
CLChristopher Lowe
Christopher Lowe
GRGordon Ritchie
Gordon Ritchie
CBConor Broderick
Conor Broderick
MPMichael Payne
Michael Payne
MRMarc G. Romney
Marc G. Romney